Negotiated prices for Kisqali and Verzenio, which the agency said cost Medicare over $1 billion in a year, would become effective starting 2028.
The FDA halted clinical trials of two gene therapies on account of a tumor found in a Hurler syndrome patient who had received RGX-111.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results